ArticleThrombosis journal2026
Characterization of anticoagulated patients in a Latin American country: indications, treatment patterns, and complications.
Article in Thrombosis journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThromboembolic disorders remain a leading cause of morbidity and mortality. Although anticoagulation therapy (AT) has reshaped practice worldwide, real-world data on AT use and outcomes in Latin America, particularly Colombia, are scarce. To bridge this gap, we established the Registro Colombiano de Clínicas de Anticoagulación (RECCANT).
objectiveTo describe the sociodemographic, clinical, and therapeutic characteristics of anticoagulated patients managed in multiple healthcare centers in Colombia.
methodsWe performed a prospective, observational, and multicenter study of adults receiving oral or parenteral anticoagulation among several Colombian institutions (2023–2025). Consecutive outpatients with an anticipated therapy duration ≥ 3 months were enrolled. Sociodemographic and clinical data were recorded prospectively. This interim analysis describes the first 2,000 patients recruited from nine institutions.
resultsOf the first 2,000 recruited patients, 58.2% were women, with a median age of 65 years (IQR 49–77). Hypertension (37.1%) and dyslipidemia (25.8%) were the most prevalent comorbidities. Venous thromboembolism (VTE) was the leading indication for anticoagulation (70.1%), followed by atrial fibrillation (14.0%). In terms of agents used, apixaban was most frequently used (37.6%), followed by rivaroxaban (26.9%), enoxaparin (17.7%), and warfarin (15.0%). Among 1,640 chronic and recent users, 152 patients (9.3%) experienced complications after AT initiation: 67.1% hemorrhagic, 27.0% thromboembolic, and 5.9% both. Major bleeding occurred in 2.6% of these patients and in 38.7% of those who experienced hemorrhagic complications. Gastrointestinal bleeding (33.3%) and ischemic stroke (46.0%) were the most frequent hemorrhagic and thromboembolic complications, respectively.
conclusionRECCANT reveals a relatively young, highly comorbid anticoagulated population in Colombia, with VTE as the main indication. High complication rates, particularly hemorrhagic events, underscore the need to strengthen existing anticoagulation care to ensure safer and more effective therapy. These findings are intended to provide preliminary insights into anticoagulation patterns among patients treated in specialized anticoagulation clinics in Colombia and may also be relevant for other Latin American settings.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.